Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) closed at $12.15 up 0.66% from its previous closing price of $12.07. In other words, the price has increased by $0.66 from its previous closing price. On the day, 0.89 million shares were traded.
Ratios:
For a deeper understanding of Day One Biopharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 10 ’24 when Blackman Samuel C. sold 30,000 shares for $13.31 per share. The transaction valued at 399,339 led to the insider holds 1,034,015 shares of the business.
Bender Jeremy sold 10,554 shares of DAWN for $139,420 on Nov 18 ’24. The CHIEF EXECUTIVE OFFICER now owns 108,377 shares after completing the transaction at $13.21 per share. On Nov 18 ’24, another insider, Blackman Samuel C., who serves as the HEAD OF R&D of the company, sold 2,206 shares for $13.21 each. As a result, the insider received 29,142 and left with 1,064,015 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 12.02 while its Price-to-Book (P/B) ratio in mrq is 2.21.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $11.13. The 50-Day Moving Average of the stock is -5.04%, while the 200-Day Moving Average is calculated to be -13.41%.
Shares Statistics:
A total of 100.81M shares are outstanding, with a floating share count of 72.64M. Insiders hold about 27.97% of the company’s shares, while institutions hold 81.16% stake in the company.
